Mission
Modern medicine has made staggering strides in treating individual diseases, yet aging itself remains the single greatest risk factor for nearly every chronic condition we face. At Kallel, we believe that longevity should not be a luxury, and extending lifespan and healthspan should not require waiting decades for novel molecules to clear the pharmaceutical pipeline. We founded our non-profit to fundamentally reshape how translational longevity research is funded, accelerated, and brought to the public.
The status quo in drug development is structurally ill-equipped for aging. Traditional investor-backed pharmaceutical companies are driven by profit margin, which creates an economic barrier: no corporation can justify the millions of dollars required to run clinical trials on off-patent, generic drugs. As a result, there are currently 10 generic drugs that have been shown to impact longevity (in some cases over 20 years ago) in ageing models supported by the NIH, but because they are “off-patent”, have not been placed into human trials because they are considered non-profitable.
Kallel exists to bypass this commercial bottleneck. Operating as a non-profit frees us from traditional market constraints. We rely on the power of human altruism; our vision is a self-sustaining research ecosystem fueled by a foundation endowment from philanthropic donors who believe that lifespan and healthspan extension is a fundamental public good.
Our work is driven by two core pillars:
Democratizing Longevity Treatment: We are launching adaptive clinical trials utilizing safe, affordable, FDA-approved generic drugs that have proven life-extending effects in the NIH-funded Mouse Interventions Testing Program (ITP). By focusing on generics, we can bypass the decades-long drug discovery lag and deliver accessible, affordable interventions to people much sooner. There are 10 drugs that are ready for human trials today; once funds are secured, for trial commencent. Moreover, we will test additional combinations of generic drugs for their ability to target known aging pathways, such as mitochondrial dysfunction, and improve lifespan and healthspan. Since there are at least 1000 FDA-approved generic drugs, we expect combinations of these to generate more candidates for human trials. The advantage of using generic drugs is that their safety has already been tested in previous human trials and thus, if we show in model systems they improve longevity, we can quickly start them in trials.
Creating an Open Hub for Longevity Research. Nature has already solved the puzzle of aging. We will expand our genomic analysis of long-lived species to extract additional targets for generic drugs. This is highlighted by our recent work on the genomic analysis of Jonathan, the world’s oldest living land animal, published in Science Advances, October 9th, 20206, where our team identified DNA methylation entropy in mitochondrial gene promoters as a target for longevity. We expect other long-lived species will provide other targets we can quickly evaluate with generic drugs. At Kallel, all of our work and research is made freely available to the rest of the aging research community, and we look forward to partnering with academic labs and other non-profits to accelerate discovery in longevity medicine.
Our work converges on a single, actionable mission: extending human lifespan and healthspan for all. This is achievable by discovering combinations of existing FDA-approved drugs that can extend human lifespan and healthspan, while simultaneously uncovering novel targets from long-lived species. With our first adaptive clinical trial targeted for late 2027 and our comparative genomic pipelines expanding rapidly, we are moving from basic aging biology to clinical reality.
Join us in building a future where longevity is within reach for everyone.